AUSTRALIA-WIDE LOW FLAT RATE $9.90

Close Notification

Your cart does not contain any items

$130

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Churchill Livingstone
28 July 2024
Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more. Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.
Edited by:   , ,
Imprint:   Churchill Livingstone
Country of Publication:   United Kingdom
Dimensions:   Height: 254mm,  Width: 178mm, 
Weight:   450g
ISBN:   9780443129216
ISBN 10:   0443129215
Series:   The Clinics: Radiology
Pages:   240
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active
Alpha and Beta Radiation for Theragnostics Neuroendocrine Tumors: Diagnostics Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors Prostate-specific Membrane Antigen: Diagnostics Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years Treatment Response Imaging in Prostate Cancer Hepatic Radioembolization: A Multistep Theragnostic Procedure

See Also